New agent ‘may slow Alzheimer’s progression’
A study shows the monoclonal antibody reduced clinical decline but is linked with brain oedema and bleeds
An experimental dementia drug that targets beta-amyloid has shown potential for slowing cognitive decline in the early stages of Alzheimer’s, drug-makers say.
The agent, lecanemab, also reduced amyloid plaques after 18 months of treatment compared with placebo, international drug manufacturers Biogen and Eisai said in a joint media statement.